New Takeda HQ Reflects Strategic Direction Amid Lingering Doubters
The official opening of Takeda's new global headquarters in Tokyo abounds with actual and implied symbolism as CEO Christophe Weber looks to take the company into the global top 10 through the Shire acquisition while maintaining its Japanese roots.
You may also be interested in...
Takeda and Shire see their £46bn combination bringing commercial and pipeline strengths across multiple therapeutic areas, along with opportunities for cost synergies and strengthening in key geographic markets.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.